The clinical trial programme for cetuximab (Erbitux) is gathering pace with new studies underway in a broad range of malignancies, according to presentations at the 13th Annual European Conference on Clinical Oncology, held this week in Paris, France. Scientists from the Fédération Francophone de Cancérologie Digestive (FFCD) announced a major pan-European collaboration to investigate whether cetuximab in combination with oxaliplatin-based chemotherapy (FOLFOX-4) will reduce disease recurrence and prolong survival in fully resected stage III colon cancer after surgery... click link for more info.